Zebrafish-Based Drug Discovery and Systems Pharmacology

Patient-Derived Cancer Xenograft Zebrafish Model

Zebrafish-Based Drug Discovery and Precision Pharmacology

次世代ゼブラフィッシュ創薬とPrecision Medicine(精密医療)


》Zebrafish-Based Drug Discovery and Pharmacophenomics


14:45-15:30 Zebrafish-Based Drug Discovery and Pharmacophenomics
Dr. Toshio Tanaka, Prof. of Mie University (Japan)
Here, we propose the strategy of zebrafish-based quantitative and systems ph
armacology, which synergistically combine the desirable features of systems
pharmacology and emerging technology of zebrafish-based phenotype screening system for functional omics and chemical biology.
Zebrafish-based systems pharmacology that analyze in vivo regulatory
networks involved in drug action can account for a drug's multiple targets
and for the effects of genomic, epigenomic, and posttranslational changes on
 the drug efficacy. The next generation discipline of systems pharmacology
aims to combine experimental analysis and computational modeling of in vivo networks with quantitative pharmacology approaches to drive the drug discovery processes, predict rare adverse events, and catalyze the practice of personalized medicine.
This new systems pharmacology can drive zebrafish-based drug discovery and shape personalized medicine.
It was found that 56% of first-in-class approvals had come from phenotypic screens, 34% had come from target-based approaches (Nat. Rev. Drug Discov. 10, 507–519; 2011).The zebrafish has become a prominent vertebrate model for disease and has already contributed to several examples of successful phenotype-based drug discovery. For the zebrafish to become useful in drug development more broadly, key hurdles must be overcome, including a more comprehensive elucidation of the similarities and differences between human and zebrafish biology.
It is hoped that the zebrafish will have a key role in accelerating the emergence of pharmacophenomics-driven drug discovery.

Workshop3: Modern workflow for drug discovery research

12 September
14:00-14:45 Cell line development and master cell bank foundation.
Malygina T. .(OPTEC LLC)
14:45-15:30 Zebrafish-Based Drug Discovery and Pharmacophenomics
Dr. Toshio Tanaka, Prof. of Mie University (Japan)

15:30-15:45 Coffe brake

15:45-16:30 sol-R multiplex reagent kits – making light work of ELISA
Andrew Goulter PhD | TTP Labtech Limited (United Kingdom)



Future of Biomedicine 2017 Conference